Shares of Iovance Biotherapeutics Inc. (IOVA) are up more than 25% in pre-market trading on Thursday, following updates from ongoing clinical trials including new interim data from phase II study of LN-145 in patients with advanced cervical cancer and phase II study of Lifileucel in advanced melanoma.
from RTT - Biotech http://bit.ly/2WGGQBr
via IFTTT
No comments:
Post a Comment